Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers

A technology for ovarian cancer and neoplasia, applied in the field of gene biomarkers, can solve the problem of unknown role of ovarian cancer

Inactive Publication Date: 2014-12-10
DCB USA +1
View PDF18 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, the role of accumulated hypermethylation and hypomethylation in ovarian cancer development and outcome remains unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
  • Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers
  • Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0057] Example 1 Identification of 25 biomarker genes of the present invention

[0058] This example is for the discovery of novel DNA methylation biomarkers for prognosis prediction and screening of ovarian cancer. Tissue samples were collected from informed and consented patients at the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. This study was reviewed by the Institutional Review Board (Institutional Review Board) and used ovarian samples from 61 independent patients, including 49 malignant and 12 benign tissues. The samples were taken during surgery and immediately frozen in liquid nitrogen and stored at -80°C until analysis. The presence of malignant cells was confirmed by histopathological examination. A gynecologic pathologist reviewed all samples for histological evaluation. Progression free survival (PFS) was defined as the time from first surgery to progressive disease. Patients with persistent disease since first-line standard ...

example 2

[0079] Example 2 Identification of 6 biomarker genes of the present invention

[0080] Tissue samples were collected from the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, with informed consent. This study was reviewed by the Institutional Review Board. The patients included 110 patients with epithelial ovarian cancer (EOS), 60 patients with a benign ovarian tumor and 28 patients with normal ovarian tissue. The diagnosis included histological type and grade. These samples were obtained during surgery and immediately frozen in liquid nitrogen and stored at -80°C until analysis. The presence of malignant cells was confirmed by histological examination. A gynecologic pathologist reviewed all samples for histological evaluation. Progression free survival (PFS) was defined as the time from first surgery to progressive disease. Patients with persistent disease since first-line standard therapy were excluded from PFS analysis. Overall survival (O...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure provides methylome analysis using DNA methylation biomarkers for predicting ovarian cancer prognosis and detecting malignant ovarian cancer. Being independent prognostic factors for patients with current treatment protocols, these DNA methylations are also important biomarkers for treating patients with individualized medicine in future including using chemotherapy, especially the demethylation agents or other epigenetic drugs.

Description

technical field [0001] The present invention relates to genetic biomarkers for predicting the risk or susceptibility of ovarian neoplasms, and / or the prognosis and malignancy of ovarian cancer. Specifically, the present invention uses DNA methylation to select candidate genes that predict the susceptibility of ovarian neoplasms and / or the prognosis and malignancy of ovarian cancer. Background technique [0002] Ovarian cancer is a serious disease that causes more deaths than any other cancer of the female reproductive system. Because of the disease's incubation period and lack of reliable screening tests, two out of three patients are diagnosed at an advanced stage, and even though many patients with tumors that have spread respond initially to a combination of surgery and cytotoxic therapy, Nearly 90% of patients relapse and inevitably die from their disease. Understanding the molecular basis of ovarian cancer may have the potential to significantly improve the diagnosis ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C07H21/04
CPCC12Q2600/154C12Q1/6886C12Q2600/118A61P15/00A61P35/00C12Q2600/106
Inventor 赖鸿政黄瑞兰
Owner DCB USA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap